Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Current Investments (2016 - 2025)

KalVista Pharmaceuticals' Cash & Current Investments history spans 11 years, with the latest figure at $220.6 million for Q2 2025.

  • On a quarterly basis, Cash & Current Investments rose 4.86% to $220.6 million in Q2 2025 year-over-year; TTM through Apr 2025 was $220.6 million, a 4.86% increase, with the full-year FY2025 number at $220.6 million, up 4.86% from a year prior.
  • Cash & Current Investments hit $220.6 million in Q2 2025 for KalVista Pharmaceuticals, down from $268.3 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for KALV hit a ceiling of $268.3 million in Q4 2024 and a floor of $50.3 million in Q1 2021.
  • Historically, Cash & Current Investments has averaged $160.0 million across 4 years, with a median of $149.4 million in 2023.
  • The widest YoY moves for Cash & Current Investments: up 267.62% in 2021, down 37.56% in 2021.
  • Tracing KALV's Cash & Current Investments over 4 years: stood at $248.9 million in 2021, then tumbled by 58.55% to $103.2 million in 2023, then soared by 160.09% to $268.3 million in 2024, then decreased by 17.79% to $220.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for KALV at $220.6 million in Q2 2025, $268.3 million in Q4 2024, and $135.8 million in Q4 2024.